2cni: Difference between revisions

No edit summary
No edit summary
Line 1: Line 1:
[[Image:2cni.gif|left|200px]]
{{Seed}}
[[Image:2cni.png|left|200px]]


<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2cni|  PDB=2cni  |  SCENE=  }}  
{{STRUCTURE_2cni|  PDB=2cni  |  SCENE=  }}  


'''STRUCTURAL INSIGHTS INTO THE DESIGN OF NONPEPTIDIC ISOTHIAZOLIDINONE-CONTAINING INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B'''
===STRUCTURAL INSIGHTS INTO THE DESIGN OF NONPEPTIDIC ISOTHIAZOLIDINONE-CONTAINING INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B===




==Overview==
<!--  
Structural analyses of the protein-tyrosine phosphatase 1B (PTP1B) active site and inhibitor complexes have aided in optimization of a peptide inhibitor containing the novel (S)-isothiazolidinone (IZD) phosphonate mimetic. Potency and permeability were simultaneously improved by replacing the polar peptidic backbone of the inhibitor with nonpeptidic moieties. The C-terminal primary amide was replaced with a benzimidazole ring, which hydrogen bonds to the carboxylate of Asp(48), and the N terminus of the peptide was replaced with an aryl sulfonamide, which hydrogen bonds to Asp(48) and the backbone NH of Arg(47) via a water molecule. Although both substituents retain the favorable hydrogen bonding network of the peptide scaffold, their aryl rings interact weakly with the protein. The aryl ring of benzimidazole is partially solvent exposed and only participates in van der Waals interactions with Phe(182) of the flap. The aryl ring of aryl sulfonamide adopts an unexpected conformation and only participates in intramolecular pi-stacking interactions with the benzimidazole ring. These results explain the flat SAR for substitutions on both rings and the reason why unsubstituted moieties were selected as candidates. Finally, substituents ortho to the IZD heterocycle on the aryl ring of the IZD-phenyl moiety bind in a small narrow site adjacent to the primary phosphate binding pocket. The crystal structure of an o-chloro derivative reveals that chlorine interacts extensively with residues in the small site. The structural insights that have led to the discovery of potent benzimidazole aryl sulfonamide o-substituted derivatives are discussed in detail.
The line below this paragraph, {{ABSTRACT_PUBMED_17028182}}, adds the Publication Abstract to the page
(as it appears on PubMed at http://www.pubmed.gov), where 17028182 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_17028182}}


==About this Structure==
==About this Structure==
Line 48: Line 52:
[[Category: Polymorphism]]
[[Category: Polymorphism]]
[[Category: Protein phosphatase]]
[[Category: Protein phosphatase]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May  3 22:35:23 2008''
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Jul 27 12:30:35 2008''

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA